Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96PN8
UPID:
TSSK3_HUMAN
Alternative names:
Serine/threonine-protein kinase 22C
Alternative UPACC:
Q96PN8; Q5TEE5
Background:
Testis-specific serine/threonine-protein kinase 3, alternatively known as Serine/threonine-protein kinase 22C, plays a crucial role in male germ cell development and mature sperm function. Its involvement in signaling pathways underscores its importance in reproductive biology.
Therapeutic significance:
Understanding the role of Testis-specific serine/threonine-protein kinase 3 could open doors to potential therapeutic strategies. Its pivotal role in sperm function and male fertility highlights its potential as a target for addressing reproductive health issues.